ImmuPharma PLC (LON:IMM) Chairman Tim McCarthy talks to DirectorsTalk about the recent progress with Lupuzor, opportunities for the company, milestones for 2016 and a re-rating for Immupharma shares?
LupuzorTM (also referred to as forigerimod, rigerimod, IPP-201101 or P140 is ImmuPharma’s lead compound and a potential treatment for lupus (or Systemic Lupus Erythematosus), a chronic, potentially life-threatening auto-immune disease. LupuzorTM has a novel mechanism of action aimed at modulating the body’s immune system so that it does not attack healthy cells, and avoids causing adverse side effects. It has the potential to halt the progression of the disease in a substantial proportion of patients.
ImmuPharma Plc is a pharmaceutical development company listed since 2006 on AIM of the London Stock Exchange (LSE:IMM), focusing on developing novel medicines with high sales potential in specialist markets with serious unmet need. ImmuPharma is led by a commercially focused Board and management team with extensive experience. For more information please go to: www.immupharma.org